Eloxx Pharmaceuticals, Inc.
Data quality: 100%
ELOX
OTC
Manufacturing
Chemicals
$0.08
$0.00
(0.00%)
Mkt Cap: 405,754.0
Price
$0.08
Mkt Cap
405,754.0
Day Range
—
52-Week Range
—
Volume
—
Open —
50D / 200D Avg
—
50D / 200D Avg
—
Quick Summary
Key Takeaways
Negative free cash flow of -6.33 M
Growth
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
N/A
ROICN/A
Net MarginN/A
Op. MarginN/A
Safety
Debt / Equity
N/A
Current Ratio0.24
Interest CoverageN/A
Valuation
PE (TTM)
-0.07
Above sector avg (-1.48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A
Price History
Financial Trends
Peer Comparison
vs Manufacturing sector median (1364 peers)
Peer Comparison
vs Manufacturing sector median (1364 peers)| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -0.1 | -1.5 |
| P/B | — | 1.6 |
| ROE % | — | -53.4 |
| Net Margin % | — | -41.5 |
| Rev Growth 5Y % | — | 1.8 |
| D/E | — | 0.3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 0.0 | Net Income (TTM) | -6.00 M |
| ROE | N/A | ROA | -99.63% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -6.33 M |
| ROIC | N/A | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 0.24 |
| Interest Coverage | N/A | Asset Turnover | 0.00 |
| Working Capital | -17.84 M | Tangible Book Value | -20.05 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0.07 | Forward P/E | N/A |
| P/B Ratio | N/A | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -1559.32% | ||
| Market Cap | 405,754.0 | Enterprise Value | 251,754.0 |
| Per Share | |||
| EPS (Diluted TTM) | -0.49 | Revenue / Share | 0.00 |
| FCF / Share | -1.25 | OCF / Share | -1.25 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 105.54% |
| SBC-Adj. FCF | -8.67 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | 0.0 | — | — | — | — |
| Net Income | -6.00 M | -36.07 M | -66.73 M | -34.58 M | -50.87 M |
| EPS (Diluted) | -0.49 | -16.65 | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -6.44 M | -34.42 M | -66.02 M | -33.46 M | -50.56 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | — | — | — | 14.59 M | 25.84 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Income Tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Total Assets | 5.27 M | 21.12 M | 45.14 M | 26.48 M | 58.95 M |
| Total Liabilities | 17.18 M | 31.78 M | 22.76 M | 16.25 M | 22.73 M |
| Shareholders' Equity | -11.91 M | -10.66 M | 22.38 M | 10.23 M | 36.21 M |
| Total Debt | 1.00 M | 11.72 M | 11.18 M | 10.72 M | 13.94 M |
| Cash & Equivalents | 4.79 M | 19.21 M | 42.27 M | 24.67 M | 22.49 M |
| Current Assets | 5.27 M | 20.13 M | 43.48 M | 25.89 M | 57.71 M |
| Current Liabilities | 17.18 M | 23.09 M | 9.96 M | 9.84 M | 11.81 M |
{"event":"ticker_viewed","properties":{"ticker":"ELOX","listing_kind":"stock","pathname":"/stocks/elox","exchange":"OTC","country":"US"}}